Canadian recommendations for the use of SGLT2i and mineralocorticoid receptor antagonists in the management of heart failure with mildly reduced or preserved ejection fraction

29 August 2026 (17:30 - 17:45)

Organised by:

Video

Slides

Sign in for access options

About the speaker

Doctor Margot Davis

University of British Columbia, Vancouver (Canada)

3 More presentations in this session

Presentation thumbnail

Canadian recommendations for the use of angiotensin receptor neprilysin inhibitor and GLP-1 RA in the management of heart failure with mildly reduced or preserved ejection fraction

Doctor S. Zieroth (Winnipeg, CA)

Presentation thumbnail

ESC recommendations for the use of SGLT2i, GLP-1 RA, mineralocorticoid receptor antagonists, and angiotensin receptor neprilysin inhibitor in the management of heart failure with mildly reduced or preserved ejection fraction

Professor R. De Boer (Rotterdam, NL)

Presentation thumbnail

What is the horizon for heart failure with mildly reduced or preserved ejection fraction?

Professor J. McMurray (Glasgow, GB)

Access the full session

Session thumbnail

Pharmacologic management of heart failure with mildly reduced or preserved ejection fraction

The Event

Event poster

ESC Congress 2026

29 August 2026 17:30 CET

You may be interested in

Congress Session

Non-steroidal mineralocorticoid receptor antagonists: current role and implementation in the management of patients with heart failure

10 May 2026

Congress Presentation

State-of-the-art lecture on contemporary therapy for HFrEF

28 August 2026

Congress Session

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure – Ask the Guidelines Task Force

27 August 2023

Congress Session

Pharmacotherapy

23 May 2023

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources